Skip to main content
OpenTrials
Completed

NCT Number: NCT03268031

Artificial Intelligence-assissted Glaucoma Evaluation

Glaucoma is currently the second leading cause of irreversible blindness in the world. Our study intends to combine clinical data of glaucoma patients in Zhongshan Ophthalmic Center with Artificial Intelligence techniques to create programs that can screen and diagnose glaucoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Artificial Intelligence Eye Diseases Glaucoma Ocular Hypertension

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, 510000, China

About this study

Glaucoma is currently the second leading cause of irreversible blindness in the world, which brings heavy burden to human society. Compared to other ocular diseases, diagnostic process of glaucoma is complicated depends on multiple test results, including visual field test, OCT, etc. How to diagnose glaucoma correctly and fast has always been a hot topic in glaucoma researches. Artificial intelligence is used to study and develop theories and methods that can help simulate and extend human intelligence, which has been utilized in a lot of research fields such as automatic drive and medicine. The study intends to combine clinical data of glaucoma patients in Zhongshan Ophthalmic Center with Artificial Intelligence techniques to create programs that can screen and diagnose glaucoma.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BCVA>0.1
  • able to complete reliable visual field test
  • no history of intraocular surgery or fundus laser

Exclusion criteria

  • unable to complete visual field test

Treatment and study plan

Visual field and OCT tests

Diagnostic Test

Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.

Primary outcomes

  1. Accuracy of diagnosis by artificial intelligence algorithm

    Time frame: from August 2017 to February 2021

    Accuracy of diagnosis by artificial intelligence algorithm and compare this result with glaucoma specialists

Secondary outcomes

  1. Sensitivity of diagnosis by artificial intelligence algorithm

    Time frame: from August 2017 to February 2021

    Sensitivity of diagnosis by artificial intelligence algorithm

  2. Specificity of diagnosis by artificial intelligence algorithm

    Time frame: from August 2017 to February 2021

    Specificity of diagnosis by artificial intelligence algorithm

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Collaborators

  • Chinese Academy of Sciences

Registry information

Official study title

Development of Artificial Intelligence-assissted Diagnostic Program of Glaucoma

Acronym: AGE

Important dates

Study start
2017
Primary completion
2019
Study completion
2020
First posted
Aug 31, 2017
Registry last updated
Oct 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.